Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
Ontology highlight
ABSTRACT: Using specimens from a phase 1b trial of the RV144 regimen in HIV-1-uninfected South Africans (HVTN 097), we profiled innate responses to the first ALVAC-HIV immunization. PBMC transcriptional responses peaked 1 day post-vaccination. Type I and II interferon signaling pathways were activated, as were innate pathways critical for adaptive immune priming.
ORGANISM(S): Homo sapiens
PROVIDER: GSE164366 | GEO | 2021/03/17
REPOSITORIES: GEO
ACCESS DATA